SmartCells CEO Reflects on Strategy Leading to $500M Exit with Merck

Beverly, MA-based SmartCells has kept a relatively low profile since it was founded seven years ago, quietly working on a potential blockbuster drug for diabetes with technology from MIT. But yesterday the drug giant Merck (NASDAQ:MRK) made headlines with its plans to buy the biotech startup for upfront and potential milestone payments of more than $500 million.

View full post on

Tags: , , , , , ,

Comments are closed.